---
title: "Pharscin Pharma: CX001 sustained-release tablets have received approval for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246947396.md"
description: "Pharscin Pharma recently received approval from the National Medical Products Administration for the clinical trial application of CX001 sustained-release tablets. This medication is used to treat postherpetic neuralgia and aims to improve patient compliance and sleep quality by reducing the frequency of administration through an improved sustained-release formulation for gastric retention"
datetime: "2025-07-02T08:48:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246947396.md)
  - [en](https://longbridge.com/en/news/246947396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246947396.md)
generator: "portal-rs"
---

# Pharscin Pharma: CX001 sustained-release tablets have received approval for clinical trials

According to the Zhitong Finance APP, Pharscin Pharma (002907.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). After review, the clinical trial application for CX001 sustained-release tablets submitted on April 16, 2025, meets the relevant requirements for drug registration, and approval has been granted to conduct clinical trials for the indication "for the treatment of postherpetic neuralgia."

CX001 sustained-release tablets are self-developed products of the company, which modify the immediate-release formulation into a sustained-release formulation (gastric-retentive sustained-release tablets). This sustained-release formulation can reduce the frequency of administration, increase patient compliance, and improve sleep quality. The indication for this clinical trial application is for the treatment of postherpetic neuralgia

### Related Stocks

- [002907.CN](https://longbridge.com/en/quote/002907.CN.md)

## Related News & Research

- [BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal](https://longbridge.com/en/news/298111133.md)
- [Trump Wants Beef Prices to Come Down, But GOP Congressman Warns Washington's Import Push Could Pull the ‘Rug Out’ From Ranchers](https://longbridge.com/en/news/297776718.md)
- [Trump expected to sign a beef-related executive order on Friday, sources say](https://longbridge.com/en/news/298061205.md)
- [16:48 ETBeverly Hills MD Dermal Repair Complex Wins Beauty Product of the Year](https://longbridge.com/en/news/297957835.md)
- [Odyssey Behavioral Healthcare Marks 10 Years with Measurable Clinical Outcomes Across Mental Health, Substance Use and Eating Disorder Programs](https://longbridge.com/en/news/297943522.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**